Login to Your Account

Mannkind's Afrezza passes FDA; next test: Commercialization

By Jennifer Boggs
Managing Editor

Friday, June 27, 2014
On its third try before the FDA, Mannkind Corp.'s inhaled insulin Afrezza (insulin human [rDNA origin]) finally won approval Friday, capping nearly eight years of dogged pursuit in the wake of the spectacular commercial failure of first-generation inhaled insulin Exubera, but an FDA nod is only the first battle.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription